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Bladder cancer is among the most common cancers in the 
UK and conventional detection techniques suffer from 
low sensitivity, low specificity, or both. Recent attempts 
to address the disparity have led to progress in the field 
of autofluorescence as a means to diagnose the disease 
with high efficiency, however there is still a lot not 
known about autofluorescence profiles in the disease. 
The multi-functional diagnostic system “LAKK-M” was 
used to assess autofluorescence profiles of healthy and 
cancerous bladder tissue to identify novel biomarkers of 
the disease. Statistically significant differences were 
observed in the optical redox ratio (a measure of tissue 
metabolic activity), the amplitude of endogenous 
porphyrins and the NADH/porphyrin ratio between tissue 
types. These findings could advance understanding of 
bladder cancer and aid in the development of new 
techniques for detection and surveillance.  
1. Introduction
Bladder cancer (BCa) is among the most common 
cancers [1]. BCa can be separated into non-muscle-
invasive (NMIBC) and muscle-invasive (MIBC) 
diseases. NMIBC is contained within the 
urothelium (the inner epithelial layer of the 
bladder) and lamina propria, however high grade 
instances of NMIBC present with the potential to 
quickly transition from NMIBC to MIBC. 
Similarly, carcinoma in situ (CIS) [2] possesses 
significant malignant potential to quickly progress 
into MIBC. BCa is conventionally detected by the 
gold standard white light cystoscopy (WLC) and 
voided urine cytology (VUC) [3] which identifies 
cytological abnormalities. Suspect tissue identified 
by WLC is confirmed by biopsy. Unfortunately, 
WLC and VUC suffer from low sensitivity, 
especially for low stage cancers such as flat 
NMIBC and CIS. VUC sensitivity for transitional 
cell carcinoma (TCC) is between 25-50% [4, 5], 
while WLC sensitivity for TCC ranges between 60-
70% [6, 7] (but can be as low as 4% for CIS cases 
[8]). The result of this low sensitivity is a high rate 
of tumour progression and recurrence, which puts a 
large burden on health services each year. Bladder 
cancers which progress to MIBC stage can often 
only be adequately dealt with by radical 
cystectomy [9]. Steps have been taken to improve on 
the low sensitivity of WLC and VUC with 
photodynamic diagnosis (PDD) using 
photosensitisers (PS). These accumulate 
preferentially in tumour tissue due to the enhanced 
permeability and retention effect [10] by retaining 
hexaminolaevulinate (HAL) [11] and 5-
aminolaevulinic acid (5-ALA) [12]. PDD is shown 
to improve the sensitivity of cytoscopic detection 
of bladder cancer compared to WLC [13] – reducing 
NMIBC recurrence rates [14] - but at the cost of 
reduced specificity due to uptake by inflamed 
healthy tissue previously treated by surgery or 
chemotherapy [7, 15]. There is a need therefore for 
novel detection techniques which possess high 
sensitivity and specificity.   
Many of the molecules present in human tissue 
naturally fluoresce, including amino acids 
(tryptophan [16, 17]), structural proteins (collagen [18] 
and elastin [19]), metabolic cofactors (NADH [20] 
and flavins [21]) and blood precursors (porphyrins 
[22]). Tissue remodelling by tumours has previously 
been shown to significantly reduce local collagen 
levels to promote invasion and metastasis [23]. 
Furthermore, metabolic disparity between healthy 
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and cancerous tissue has been extensively 
explained by the Warburg effect [24]. The optical 
redox ratio (ORR) takes into account the 
accumulation of NADH in cancer cells by rationing 
NADH content to flavin content (NADH/Flavin) to 
give a measure of the extent of the Warburg effect. 
The ORR has previously discriminated between 
healthy and cancerous cells [25-27], including by 
ourselves in bladder cancer [28]. Alfano et al. were 
among the first to discuss autofluorescence 
spectroscopy for cancer detection, applying UV 
fluorescence spectroscopy to the identification of 
breast and lung cancers [29] and characterising 
flavin and porphyrin fluorescence in mouse bladder 
tumours [30].  Autofluorescence spectroscopy for 
cancer diagnosis in a wide range of tissues has 
since been covered comprehensively [31], including 
for bladder cancer [32-35]. Early research comparing 
autofluorescence with PDD suggested that UV 
autofluorescence spectroscopy was a more 
effective tool for tumour margin demarcation than 
PDD [36]. D’Hallewin et al. previously reviewed the 
field of bladder autofluorescence spectroscopy [37], 
concluding that tissue thickening was the major 
contributor to significant differences between 
healthy and cancerous tissue (measured as the 
fluorescence of collagen and NADH), in keeping 
with findings from collagen/NADH ratios in 
prostate cancer [38] and Barrett’s oesophagus [39]. A 
limitation of this method is its application for the 
detection of flat CIS, which does not cause tissue 
thickening. In light of this, new biomarkers and 
diagnostic ratios for autofluorescence detection of 
bladder cancer are required which are independent 
of tissue thickening. The limitation to our 
understanding of the contributions of individual 
fluorophores to complex tissue spectra is being 
addressed by contemporary research [38, 40], 
allowing us to better address this issue. Anidjar et 
al. attempted to address this by studying tryptophan 
fluorescence in tissue, recording diagnostic worth 
for CIS [41]. Recently, our group identified 
progressive changes in the ORR of bladder cancer 
organoids [42]. As the ORR is a measure of 
metabolic activity in cells and tissues, it may 
provide worth to better understand bladder 
autofluorescence irrespective of tissue thickening. 
We were therefore interested to see whether this 
phenomenon would be reproduced in human biopsy 
samples. We sought to investigate whether the 
decreased ORR seen in progressing bladder cancer 
organoids would be corroborated in human bladder 
tissue.  
Another limitation of autofluorescence 
spectroscopy is scattering and absorption of UV 
light, impeding its penetration deeper into tissue. 
There is current interest in the study of tissue 
optical properties at longer wavelengths, into the 
optical window (650-950nm) [43]. Our secondary 
objective, therefore, was to use longer wavelength 
light (635nm) to investigate whether endogenous 
porphyrins can be used as a diagnostic marker of 
bladder cancer. Research into the relationship 
between porphyrin levels and bladder cancer 
generally relates to their accumulation during PDD, 
therefore the profile of endogenous porphyrin in 
non-sensitised tissue is poorly understood. 
Porphyrins have been shown to accumulate in oral 
cancer [44] and in the blood [22] and tissue [45] of 
mice bearing renal cell carcinoma. We therefore 
considered that endogenous porphyrins may 
likewise accumulate in non-sensitised human 
bladder tissue. Finally, we sought to corroborate 
previous findings by Aboumarzouk et al [35] of a 
statistically significant difference in the ratio of 
NADH/porphyrins in bladder cancer. Our main 
hypotheses were: bladder cancer tissue will possess 
a reduced ORR, an increased endogenous 
porphyrin concentration and a reduced 
NADH/porphyrin ratio relative to healthy tissue. 
Our research findings confirm these hypotheses. 
These findings may better inform our 
understanding of autofluorescence analysis of 
bladder cancer through the corroboration of a lab-
based organoid model and through the 
identification of a suitable cancer biomarker at a 
longer wavelength (endogenous porphyrins). 
Ultimately, these biomarkers and diagnostic ratios 
may help to better address shortcomings of 
autofluorescence diagnosis by providing new 
biomarkers and diagnostic ratios which are not 
dependent on tissue thickening. These findings also 
contribute to the development of a multi-functional 
system with which the oxygenation, blood flow and 
autofluorescence status of human bladder tissue can 
be studied simultaneously.  
2. Experimental 
2.1 Laser Setup 
The commercial unit “LAKK-M” (“Multi-
functional laser analyser of capillary blood flow”) 
(SPE-LAZMA, Moscow, Russia) was used for all 
fluorescence spectroscopy measurements. This 
facilitates multi-wavelength optical excitation and 
detection of fluorescence signals. The central 
functional unit contains the light sources used for 
measurements (1.5mW 365nm LED for UV 
excitation and 5.5mW 635nm semi-conductor laser 
for red excitation). The system also contains blue 
(450nm) and green (532nm) laser sources. Blue 
light can also be used to excite FAD fluorescence, 
however UV excitation is more stable for studying 
the optical redox ratio. Tissue fluorescence under 
green excitation could not be attributed to any 
known fluorophores so was omitted from analysis. 
The laser sources are connected to optical fibres 
and combined with their respective detection fibres 
into a single probe of outer assembly diameter of 
2mm (the distance separating each source from its 
detector being 0.5mm), which forms the optical 
probe of the LAKK-M system. The probe is 
brought into contact with the biological object (or 
inserted into the cuvette for fluorophore 
measurements), following which the laser is 
switched on, incident laser light is delivered by the 
particular excitation fibre to the tissue, transformed 
by the tissue and the transformed light is received 
by the respective detection fibre housed 0.5mm 
away. Penetration depth of light into tissue ranges 
between 0.5-1mm, depending on the source used. 
Optical filters are used to attenuate (roughly x1000) 
the intensity of back-scattered light received and 
displayed by the detector. The detection fibres are 
coupled to a charge coupled device (CCD) and an 
inbuilt spectrometer with polychromator and 
diffraction grating to detect fluorescence between 
350-823nm at 0.2nm increments. The information 
from the spectrometer (fluorescence spectra 
including intensity of fluorescence and individual 
biomarker values) is displayed on the controlling 
laptop (to form a feedback loop) using the custom 
made software “LDF 3.1” (SPE-LAZMA), from 
which fluorescence is quantified in arbitrary units 
(AU) by fluorescence intensity at designated 
wavelengths. The setup and function of the LAKK-
M system is explained in greater detail previously 
by Dunaev et al. [46] while the general setup is 
depicted in Figure 1. An example of spectral 
readout of UV-excited tissue fluorescence by the 
custom-made software is depicted in Figure 2, 
showing the back-scattered light, tissue 
fluorescence spectrum, biomarker amplitude values 
and the calculated diagnostic ratios. The LAKK-M 
system is switched on at least 30 minutes prior to 
any measurements to warm-up and initialise and all 
measurements are performed in darkness.   
2.2 Fluorophore Spectroscopy 
Fluorophores (NADH, FAD and Protoporphyrin IX 
(PpIX)) were purchased as powders from Sigma-
Aldrich (Gillingham, Dorset, UK) and prepared to 
1M solutions in phosphate buffered saline (PBS). 
The LAKK-M device was used to measure the 
fluorescence of the solutions in matte black 
cuvettes of known optical properties. NADH and 
FAD were excited at 365nm and measured across 
400-823nm. PpIX was excited at 635nm and 
measured across 650-823nm. 
2.3 Patient Recruitment 
Ethical approval was obtained from NRES London 
Central Ethics Committee, UK, for “ABLADE: 
Diagnosis of bladder cancer using multifunctional 
laser” (REC reference 14/LO/1076, approved 
17.06.14) sponsored by TASC (University of 
Dundee/NHS Tayside). The ethical approval 
granted 12 months for the recruitment of 20 
patients to the study under informed consent. The 
inclusion criteria were: patients between the ages of 
16-90 with suspected bladder tumour undergoing 
cystoscopic examination by WLC, with 
transurethral resection of bladder tumour (TURBT) 
at Ninewells Hospital, Dundee. Participants were 
identified and approached solely by the research 
team. Participants were given a participant 
information sheet (PIS) and provided informed 
consent by signing and initialling a consent form.  
2.4 Tissue Fluorescence Spectroscopy 
Tissue was delivered by surgical staff to the 
research team, either in the workroom adjacent to 
the urology theatre (in Ninewells Hospital, 
Dundee), or in the microscopy laboratory (within 
the Division of Imaging and Technology, 
University of Dundee, Ninewells Hospital, 
Dundee). Tissue was placed mucosal side face up 
where possible (some tissue was obscured by crush 
and cautery artefacts) in a matte black cuvette of 
known optical properties. The optical probe of the 
LAKK-M system was brought into contact with the 
tissue surface and held for 10 seconds to steady, 
following which fluorescence spectra were taken 
from tissue at both 365nm and 635nm excitation. 
One measurement was taken from each sample 
received, comprising one spectrum excited at 
365nm (UV) and one spectrum excited at 635nm 
(red). Often, several samples were received from a 
similar site on a patient. These were considered as 
independent samples for the sake of analysis. The 
122 (89 cancerous and 33 healthy) entries in the 
dataset for analysis therefore each represent one 
measurement of one independent sample. The 
fluorescence spectra received from tissue were 
saved in the “LDF 3.1” inbuilt database, denoted by 
patient ID and by tissue location. The pathology 
opinion of the tissue was not known to the research 
team at the time of analysis. Samples were 
delivered to the lab in closed tissue tubs and 
measurements were performed in darkness to 
minimise photo-bleaching. Immediately after 
analysis, the biopsy samples were delivered to the 
pathology lab (in Ninewells Hospital, Dundee) by a 
member of the research team. The process of 
receiving samples, measuring and returning to the 
pathology lab took no longer than 2 hours in each 
instance.  
2.5 Histopathology as reference standard 
All pathology analyses were independently 
provided by an experienced, qualified NHS 
pathologist with no involvement in the research 
team and no knowledge of the spectroscopy results. 
From 20 participants, 122 samples were received 
(therefore 122 independent measurements each of 
NADH, flavin, ORR and porphyrins). Of the 122 
samples, 33 were healthy and 89 were diagnosed as 
bladder cancer. Of the 33 healthy samples, 10 were 
normal (non-inflamed) while 23 were inflamed 
(including cystitis cystica). Within the 89 bladder 
cancer samples, 6 were CIS, 7 were squamous cell 
carcinoma (SCC) and 76 were transitional cell 
carcinoma (TCC). Of the TCC samples: 30 samples 
were Ta (tumour is contained within the 
urothelium); 20 were T1 (tumour extends into 
connective tissue); 26 were T2 (tumour invades 
into muscle). All 7 of the SCC samples were stage 
T2.  
2.6 Data Analysis 
Sample spectra were exported as ASCII files and 
combined, plotted and visualised using Origin Pro 
8 analysis software. From the custom-made 
LDF3.1 software, amplitudes of fluorescence for 
specific fluorophores of interest were recorded, in 
keeping with previous work by Dunaev et al [46], 
Akbar et al. [47] and Smirnova et al.[48]. The 
excitation and emission wavelengths for the 
endogenous fluorophores of interest were as 
follows (Table 1): 
Table 1 Endogenous fluorophores studied using the 
LAKK-M system 
Fluorophore Excitation (nm) Emission (nm) 
NADH 365 490 
FAD 365 550 
Porphyrin 635 710 
 
To ensure that porphyrin amplitude of fluorescence 
was not being affected by measurement angle, 
tissue turbidity or refractive index, the coefficient 
of fluorescence contrast (Kf) of porphyrin was also 
calculated according to previous methods [49] and 
compared for statistical significance. Fluorescence 
intensity was also quantified by area under the 
curve (AUC) calculation to corroborate spectral 
figures. Sample AUC values were calculated for 
365nm excitation as Σ[I400-823]/5 and for 635nm 
excitation as Σ[I650-823]/5. Biomarker amplitude 
values, porphyrin Kf, ORR (NADH/FAD) and 
NADH/porphyrin values for each sample, 
alongside both UV and red AUC values, were 
collated in a master file using Microsoft Excel, 
alongside tissue opinion (1 = healthy, 2 = cancer). 
The study master file was imported to R Studio for 
statistical analysis. As populations were not 
normally distributed, populations were compared 
using the analysis of variance (ANOVA) function 
in R Studio. Statistical analyses were performed to 
calculate the p value in every instance, with p<0.05 
considered statistically significant. Non-inflamed 
and inflamed healthy tissue were compared by 
ANOVA for each parameter. No statistically 
significant differences were found between 
populations, therefore they were considered as a 
single population (healthy) for the purpose of the 
study. Data were log transformed during analysis to 
ensure better fit within Q-Q and residuals versus 
leverage plots. For factors with statistically 
significant differences between populations, bar 
charts were generated in Origin Pro 8 depicting the 
population mean +/- the standard error of the mean 
(SEM) for opinion (healthy vs cancer). For 
statistically significant factors, receiver operating 
characteristic (ROC) curves were generated using 
Origin Pro 8 analysis software to evaluate the 
sensitivity/specificity trade-off of a diagnostic 
parameter at different diagnostic thresholds. For 
ROC curves, AUC was calculated automatically, 
with values ranging from 0.5 (worthless) to 1 
(excellent).
 Figure 1 Schematic showing the setup of the LAKK-M laser system and interaction with biological object (biopsy tissue) 
 
Figure 2 LAKK-M software interface showing the back-scattered laser light (A), tissue fluorescence spectrum (B), 
amplitudes of fluorescence for fluorophores of interest (C) and calculation of diagnostic ratios (D)
3. Results and discussion 
Average fluorescence spectra from tissue at 365nm 
excitation were superimposed over spectra received 
from 1M solutions of reduced Nicotinamide 
Dinucleotide (NADH) and Flavin Adenine 
Dinucleotide (FAD), excited at 365nm (Figure 
3A). Average fluorescence spectra from tissue at 
635nm were superimposed over spectrum received 
from 1M solution of Protoporphyrin 9 (PpIX) 
excited at 635nm (Figure 3B). From Figure 3A it 
can be seen that the spectral shape of tissue under 
365nm excitation suggests a significant 
contribution from NADH (main tissue peak at 
490nm) and FAD (shoulder peak at 550nm), while 
fluorescence spectra of tissue under 635nm 
excitation (Figure 3B) suggests a significant 
contribution from porphyrins (main tissue peak 
700-710nm). Slight differences in full width at half 
maximum (FWMH) between tissue fluorescence 
and PpIX may be explained by overlapping 
fluorescence from the presence of different forms 
of porphyrin in tissue (coproporphyrin, for 
example). Differences in line shape of the UV 
spectra suggested possible differences in ORR 
values between populations. Furthermore, from the 
average red fluorescence spectra it can be seen that 
the intensity of fluorescence from cancer samples is 
almost double that of healthy tissue. AUC analysis 
revealed there were no statistically significant 
differences in total fluorescence intensity (reflected 
by spectral amplitude) under 365nm excitation 
(p=0.519), however there was a statistically 
significant difference in total fluorescence intensity 
under 635nm excitation (p=0.00265). This 
difference is attributable to the non-normal 
distribution of tissue fluorescence intensity, which 
may be more exaggerated at UV wavelengths 
where blood and other tissue scatterers have a 
greater effect on measured autofluorescence. 
Cancer samples were subsequently separated into 
CIS (n=6), SCC (n=7) and TCC (n=76) cases and 
plotted alongside healthy and cancer average 
spectra for both 365nm excitation (Figure 4A) and 
635nm excitation (Figure 4B). From these figures 
we can see clearly that the average cancer spectra 
(red) are largely dictated by contribution from TCC 
samples (pink) in both cases, as average spectra are 
almost identical. CIS samples were found to 
display the lowest average intensity AUC values 
under 365nm excitation, while SCC samples 
displayed the highest. Further observation indicates 
that the NADH/FAD ratio (ORR) was lowest in 
CIS and SCC samples. CIS and SCC populations 
were too small to perform meaningful AUC 
analysis and therefore would benefit from 
corroboration in a larger study. 
Optical redox ratio (ORR) values for each sample 
were calculated and compared for statistically 
significant differences. The mean +/- SEM values 
for healthy and cancerous bladder tissue are 
depicted below (Figure 5A). A statistically 
significant decrease in the ORR of cancer tissue 
compared to healthy can be seen (p = 0.00891). 
This result is in keeping with our previous finding 
of progressive reductions in the ORR of bladder 
cancer organoids. Crucially, this finding reveals 
that although there were no significant differences 
in fluorescence intensity, spectral line shape has 
potential to be employed diagnostically. Small 
sample number of CIS and SCC tissues prevented 
meaningful independent analysis, necessitating 
further study. The amplitude of fluorescence of 
porphyrins was recorded and analysed for 
statistically significant differences. The mean +/- 
SEM values for porphyrin fluorescence amplitude 
in healthy and cancer tissue are depicted below 
(Figure 5B). From this data it can be seen that 
porphyrin levels in cancer samples are greatly 
increased compared to healthy samples. This 
difference was found to be extremely statistically 
significant (p=0.00241). Porphyrin Kf values were 
also found to be statistically significant (p=0.0144), 
indicating tissue optical properties had little effect 
on porphyrin measurements. From Figure 5C, the 
average +/- SEM values for the NADH/porphyrin 
ratios for healthy and cancer samples can be seen. 
The difference between samples was found to be 
extremely statistically significant (p=0.00624). 
ROC curves were generated for all factors to 
determine their diagnostic worth. Figure 6 below 
details these ROC curves. From Figure 6A, the UV 
ORR displays some diagnostic worth for the 
detection of bladder cancer (AUC value = 0.64), 
however when comparing healthy samples to CIS 
samples alone (n=6) (Figure 6B), the AUC value 
increases to 0.83, indicating a much more 
promising diagnostic test. Considering porphyrins 
(Figure 6C) the AUC value suggests a test with 
greater diagnostic worth than ORR for all bladder 
cancers (AUC = 0.71), at the expense of a reduced 
performance against CIS (AUC = 0.63). Finally, 
the ROC based on the ratio of NADH to porphyrins 
(Figure 6D) was found to have an AUC of 0.64. 
The AUC value for NADH/porphyrin detection of 
CIS was 0.69.  
It was hypothesised that bladder cancer tissue 
would exhibit a reduced ORR compared to healthy 
tissue. Furthermore, owing to malfunctions in the 
heme biosynthetic pathway of cancer cells (the 
basis of PDD) and previous work by Aboumarzouk 
et al [35], it was hypothesised it would be possible to 
detect an elevated level of endogenous porphyrins 
and a reduced NADH/porphyrin ratio in cancer 
tissue compared to healthy control. Results confirm 
these hypotheses. Firstly, it was demonstrated that 
tumours exhibit a reduced ORR compared to 
healthy tissue. This is in keeping with our own 
previous findings in an organoid model of bladder 
cancer [42]. Most contemporary focus on the ORR 
suggests that the metabolic alterations which occur 
during cancer development skew the degree to 
which cancer cells use their electron transport 
chain, thus causing accumulation of NADH in 
cancer cells. We ourselves have previously 
confirmed this finding in bladder cancer cell lines 
[28], however the ORR has not been extensively 
covered regarding human bladder tissue. At the 
tissue level other fluorophores may contribute to 
the complex fluorescence spectrum obtained under 
UV (365nm) illumination, such as the structural 
proteins collagen and elastin, although the spectral 
overlap from these proteins past 450nm was shown 
to be minimal [50]. Previously, Mayevsky et al. 
described a multi-parametric sensing system 
similar to the LAKK-M, using it to study NADH 
fluorescence up to 480nm [51] so we consider that 
this is the major contributing fluorophore up to 
500nm. Comparisons between average tissue 
fluorescence under UV illumination and the 
endogenous fluorophores NADH and FAD confirm 
that these are the major contributing fluorophores 
to tissue fluorescence at this wavelength, indicated 
by the lack of definitive tissue fluorescence peaks 
<490nm. ROC curve analysis of the ORR suggests 
it displays some potential as a diagnostic tool, but 
is particularly effective at detecting CIS (based on a 
small sample number). CIS is commonly missed 
during WLC and displays potential to progress into 
MIBC, therefore new techniques for its detection 
are crucial. Particular effectiveness for the ORR in 
detecting CIS also suggests this phenomenon is 
independent of tissue thickening. Future studies 
should therefore seek to corroborate these findings 
regarding the ORR, with a particular focus on an 
increased population of CIS samples.  
Tissue photo-bleaching and fading is a common 
concern in tissue spectroscopy, caused by the 
exhaustion of tissue fluorophores by irradiating 
light (specific and non-specific) [52]. NADH is a 
particular subject of photo-bleaching in tissue [53]. 
To overcome the non-specific photo-bleaching of 
tissue autofluorescence in our study, samples were 
transported to the analysis lab and measured in 
complete darkness. Each sample was irradiated by 
low power lasers (<6mW) for at most 10 seconds, 
thereby minimising photo-bleaching. As all 
samples were measured identically, the effects of 
photo-bleaching will have a minimal effect on our 
results. Furthermore, tissue NADH 
autofluorescence is known to alter after tissue has 
been removed from the body. This is due to the 
removal of blood supply and oxygenation from 
excised tissue, altering its metabolic profile. 
Anoxic and hypoxic conditions have been shown to 
cause increases in relative NADH fluorescence 
(reviewed by Mayevsky et al. [54]). NADH and 
ORR values are therefore likely altered ex vivo 
compared to in vivo analyses, however this is not a 
methodological concern for our study. As all 
samples analysed in this study (both healthy and 
cancer) were processed and measured identically, 
and all analyses were carried out < 2 hours post 
resection, we consider that the phenomenon of 
NADH fluorescence alteration should have 
minimal impact on our findings ex vivo as we 
directly compared the two populations. We assume 
that NADH perturbation occurs at similar rates in 
healthy and cancerous tissue, although future 
studies should seek to corroborate this. Future ex 
vivo analysis using the same technique may benefit 
from storing excised tissue in culture media, as this 
has been shown to maintain tissue autofluorescence 
profiles up to 4 hours post-excision [55]. The 
application of this technique in vivo should take 
into account the changes to NADH 
autofluorescence in excised tissue. In vivo, tissue 
may be expected to display significantly different 
fluorescence intensities alongside altered ORR 
values. Future studies may benefit from directly 
comparing the same bladder samples measured in 
vivo and ex vivo at various time points to improve 
understanding of NADH dynamics. 
 
Figure 3  Average fluorescence spectra of healthy (solid black line, n = 33) and cancer tissue (dotted black line, n = 89) 
under UV (A) and red excitation (B): In (A), samples are compared with UV fluorescence of NADH (solid red line) and 
FAD (dotted red line); in (B), samples are compared with red fluorescence of Protoporphyrin IX (solid red line) 
 Figure 4 Line graphs charting tissue fluorescence under UV (A) and red excitation (B) for healthy (black line, n = 33), 
cancer average (red line, n = 89), CIS (blue line, n = 6), TCC (magenta line, n = 76) and SCC (orange line, n = 7) 
 
Figure 5 Bar charts showing the average +/- SEM values for ORR (A), porphyrin amplitude (B) and NADH/porphyrin ratio 
(C) values. In each instance, healthy average (n=33) is depicted in white and cancer average (n=89) is depicted in grey 
 
Figure 6 Receiver operating characteristic (ROC) curves depicting the diagnostic accuracy (1-specificity vs sensitivity) of 
UV ORR (A), UV ORR for just CIS samples (B), porphyrin amplitude (C) and NADH/porphyrin ratio (D)  
Our findings in this paper contrast our previous 
findings of elevated ORR at the cellular level [28], 
however they may be a result of metabolic 
abnormalities across a range of different cell types, 
including cancer cells themselves and surrounding 
healthy urothelium and fibroblasts. Regarding 
porphyrin levels, the statistically significant 
increase in porphyrin levels in cancer tissue 
suggests a selective accumulation similar to that 
which is witnessed in PDD but without the need for 
PS administration. Furthermore, ROC calculations 
suggest that this biomarker possesses potential for 
diagnosis. One of the largest limitations to PDD is 
its reduced specificity. In particular, inflamed 
benign tissue is often recorded as cancer under 
PDD, owing to the leaky vasculature of tissue 
previously treated by chemotherapy or surgery. 
This results in increased false positive rates and a 
number of unnecessary invasive biopsies. That a 
statistically significant difference in endogenous 
porphyrin levels between healthy (including 
inflamed tissue) and cancer was observed suggests 
in future it may be possible to quantify porphyrin 
levels in non-sensitised tissue with the ability to 
discern between inflamed and cancer tissue. 
Endogenous porphyrins have previously been 
shown to be measurable at low levels across most 
aerobic human tissue [56], being excreted in the 
urine. Increased endogenous porphyrin levels have 
previously been observed in renal cell carcinoma 
[45]. Similarly, iron levels (the ultimate product of 
the porphyrin biosynthetic pathway) have been 
shown to preferentially accumulate in mouse 
mammary tumours [57] where they have been 
suggested to play a role in tumour cell survival and 
progression. Endogenous porphyrin fluorescence 
has previously been described in non-sensitised 
oral mucosa, even in healthy tissue [58]. Oral 
mucosa possesses similar structure to that of the 
bladder, therefore we consider that non-sensitised 
healthy bladder would likewise present some 
endogenous porphyrin fluorescence. In order to 
better exploit the tissue optical window and avoid 
fluorescence contributions from other fluorophores 
at lower wavelength (for instance, FAD and 
lipofuscin at 405nm), we studied the secondary 
porphyrin peak at 635nm excitation/710nm 
emission. This is in keeping with previous work in 
oral mucosa - in which identical measurement 
parameters observed increased endogenous 
porphyrin fluorescence in tumour tissue with small 
fluorescence signal from healthy tissue [49] – and in 
PDD of bladder TCC [59]. Average fluorescence 
from both tumour and healthy tissue was low under 
red excitation, compared with tissue fluorescence 
under UV excitation, reflecting small but detectable 
concentration of porphyrin in non-sensitised 
bladder tissue. In addition to intensity of porphyrin 
fluorescence, we also observed statistically 
significant differences in coefficient of fluorescent 
contrast (Kf) for porphyrin values between healthy 
and cancer, indicating that differences are due to 
fluorescence as opposed to other factors such as 
tissue refractive index, turbidity, etc. Previously, it 
has been suggested that chronic hypoxia is un 
underlying factor of increased porphyrin levels in 
oral mucosa [49], therefore the elevated porphyrin 
level and, more importantly, the reduced 
NADH/porphyrin values observed in bladder 
cancer may reflect an effect of tissue hypoxia on 
the reduction of cell metabolic activity. One 
concern for the application of our technique is its 
low applicability to CIS detection in a small sample 
size. Theoretically, the use of longer wavelengths 
of light to investigate tissue should allow deeper 
penetration into tissue and the detection of a greater 
number of flat lesions (for instance, CIS), therefore 
it may be that the metabolic perturbations resulting 
in increased porphyrin levels in obvious bladder 
cancer are not at play in pre-cancerous lesions. 
Finally, NADH/porphyrin levels were observed to 
be decreased in cancer samples, in keeping with 
previous research findings [35].  
Uncertainty of presented average spectra is another 
common concern when disseminating 
spectrometric findings. To address this we 
performed AUC analysis on spectra excited from 
tissue excited at 365nm and 635nm. In keeping 
with previous research in the field, average UV 
(365nm) induced fluorescence AUC value was 
greater in healthy tissue than in cancer, however 
this was not statistically significant. This could be 
due to the effects of tissue thickness on amplitude 
of fluorescence (which ranged from 2-15mm) and 
also angle and firmness of application of the 
diagnostic probe to tissue. AUC analysis of 635nm 
excited tissue spectra revealed a statistically 
significant difference, reflecting the robustness of 
the presented spectra. Diagnostic ratios such as the 
ORR and NADH/Porphyrin ratio are less affected 
by these factors and are therefore more robust 
measurements for diagnosis. This study has not 
only corroborated previous findings by ourselves 
[42] and others [35] but also applied findings from 
other forms of cancer [45] to the identification of a 
novel biomarker for bladder cancer (endogenous 
porphyrins). As this was a pilot study of 20 
participants, it would be of worth to expand this 
study with particular focus on diagnostic ratios 
such as ORR and NADH/porphyrins with particular 
focus on their applicability to CIS and early stage 
tumours. The LAKK-M system has not previously 
been used for the study of bladder cancer tissue, 
however understanding of the autofluorescence of 
bladder cancer [33, 60] and development of the 
LAKK-M for the study of fluorophore variability in 
healthy volunteers [46] and the diagnosis of 
cardiovascular disease [47] suggests its worth as a 
diagnostic tool. Furthermore, efforts are ongoing to 
better understand the bladder tissue fluorescence 
spectra in health and disease by using tissue 
fluorescence simulation models [61, 62]. Combination 
of fluorescence data with tissue simulations will 
allow delineation of the contribution of 
fluorophores such a NADH, FAD and collagen to 
recorded fluorescence. The LAKK-M system also 
contains sources for laser Doppler flowmetry 
(LDF) and tissue reflectance oximetry (TRO) 
which have previously been assessed from a 
diagnostic perspective [63]. LDF has been used to 
identify and characterise interstitial cystitis [64] 
while tumour hypoxia is a much-studied subject 
[65]. Identification and substantiation of suitable 
biomarkers of bladder cancer using the 
autofluorescence spectroscopy channel may allow 
the LAKK-M system to be developed into an 
effective multi-functional diagnostic tool for 
bladder cancer.  
Application of the LAKK-M system for In Vivo 
study and clinically will rely on a number of 
modifications to the system. The design of the 
LAKK-M system - with a central functional unit 
and external optical probe - is well suited to clinical 
application. The optical probe containing the 
excitation and detection fibres is roughly 1M in 
length, therefore it should theoretically be suitable 
for trans-urethral application. A limitation to the 
system is its lack of imaging capability, relying 
instead on spectral readouts. For this reason, 
clinical application of the system should be done so 
alongside white light cystoscopy to give the 
research team a better visualisation of tissue. One 
further limitation to the LAKK-M system is the 
measurement geometry. In order to receive useful 
diagnostic information, the optical probe must be 
brought gently into contact with the tissue of 
interest. This may be afforded by conjunction with 
a rigid or flexible cystoscope. Previously, 
Aboumarzouk et al. described a setup using the 
WavSTAT system, whereby a clamping device 
holds the probe in place during spectral analysis 
[35]. A similar setup may be employed with the 
LAKK-M optical probe to ensure sufficient contact 
between probe and tissue. The diameter of the outer 
assembly of the optical probe (2mm) should fit 
within the narrow confines of the urethra, even 
alongside a cystoscope, although the optical probe 
is modifiable to the addition or removal of 
unnecessary fibres (for instance, the probe diameter 
could be minimised by removing all but the 365nm 
and 635nm sources and detector). Finally, 
cystoscopic application necessitates sterilisation to 
avoid infection, which may be afforded by 
disposable sheaths to cover the optical probe. These 
modifications would allow the LAKK-M system to 
be applied in a clinical setting. 
Conclusion 
In conclusion, this pilot study into the 
autofluorescence profiles of healthy and cancerous 
human bladder tissue using the MLNDS “LAKK-
M” has identified three main parameters with 
which to detect bladder cancer. These findings 
improve understanding of the contribution and 
dynamics of several endogenous fluorophores to 
bladder cancer fluorescence spectra, identifying 
potential novel biomarkers with which to detect the 
disease. The LAKK-M system had not previously 
been used to study bladder cancer, however these 
findings present immense promise for the system to 
be developed into a multi-functional minimally 
invasive system for the diagnosis of the disease. 
The findings presented in this pilot study would 
benefit from corroboration in a large scale study, 
with particular focus on the discrimination of CIS.  
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